Prof. Michael Shapira is a leading Israeli hematologist and oncohematologist. He is Head of the Department of Hospitalization and Outpatient Treatment at the Hematology Center of the Suraski Clinic.
His main area of expertise is the diagnosis and treatment of diseases of the blood, lymphatic system and oncohematologic diseases in adults.
Prof. Michael Shapira has received numerous awards and prizes for his research, teaching and medical work. He has an exceptionally positive and grateful feedback from his patients.
The doctor’s total clinical experience is more than 30 years.
Professor Shapira is an internationally recognized expert in the treatment of:
Prof. Shapira is a world-renowned specialist in bone marrow transplantation, including in elderly patients.
When performing bone marrow transplants in adult patients, Prof. Michael Shapira and his colleagues utilize the most modern, innovative methods of medicine.
In parallel with his medical practice, he was involved in research, teaching and specialized in hematology.
Michael Shapira is the principal investigator in several clinical trials. During his time at the clinic, he developed and implemented new therapeutic and research techniques: hematopoietic stem cell transplantation in the elderly; the use of undifferentiated cells to restore organ function; and the treatment of graft versus host complications using innovative techniques including novel agents, special procedures and local therapies.
The professor’s methodology proved that several factors (general state of performance, active clinical problems, past medical and surgical history, eating habits) cumulatively influence the indications for transplantation. Only consideration of all prerequisites can provide an objective picture when prescribing a transplant procedure.
Thus, many patients, including those over 70 years of age, have undergone allogeneic transplantation of undifferentiated cells. Several innovative treatment protocols have been developed for this purpose and are used for transplantation in high-risk patients.